- Stocks
- Healthcare
- NASDAQ: PRAX

Price (delayed)

$59.5

Market cap

$1.06B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$9.17

Enterprise value

$913.35M

Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance. Praxis is applying insights

PRAX's equity has soared by 82% from the previous quarter

PRAX's EPS has surged by 80% year-on-year and by 38% since the previous quarter

The revenue has increased by 21% year-on-year but it has declined by 19% since the previous quarter

The gross profit rose by 21% year-on-year but it has declined by 19% since the previous quarter

What are the main financial stats of PRAX

Market
Valuations
Earnings

Shares outstanding

17.76M

Market cap

$1.06B

Enterprise value

$913.35M

Price to earnings (P/E)

N/A

Price to book (P/B)

2.43

Price to sales (P/S)

632.44

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

515.72

Revenue

$1.77M

EBIT

-$123.74M

EBITDA

-$122.42M

Free cash flow

-$95.26M

Per share
Balance sheet
Liquidity

EPS

-$9.17

Free cash flow per share

-$5.06

Book value per share

$24.5

Revenue per share

$0.09

TBVPS

$23.43

Total assets

$441.06M

Total liabilities

$21.96M

Debt

$1.95M

Equity

$419.1M

Working capital

$336.1M

Debt to equity

0

Current ratio

17.3

Quick ratio

17.06

Net debt/EBITDA

1.17

Margins
Efficiency
Dividend

EBITDA margin

-6,912.3%

Gross margin

100%

Net margin

-6,987%

Operating margin

-7,492.7%

Return on assets

-55.9%

Return on equity

-61.5%

Return on invested capital

-143.8%

Return on capital employed

-29.4%

Return on sales

-6,987%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Praxis Precision Medicines stock price performed over time

Intraday

3.08%

1 week

2.69%

1 month

12.58%

1 year

179.34%

YTD

167.06%

QTD

43.86%

How have Praxis Precision Medicines's revenue and profit performed over time

Revenue

$1.77M

Gross profit

$1.77M

Operating income

-$132.7M

Net income

-$123.74M

Gross margin

100%

Net margin

-6,987%

The net margin has increased by 35% year-on-year but it has declined by 22% since the previous quarter

PRAX's operating margin is up by 31% year-on-year but it is down by 26% since the previous quarter

The revenue has increased by 21% year-on-year but it has declined by 19% since the previous quarter

The net income has grown by 21% YoY

What is Praxis Precision Medicines's growth rate over time

What is Praxis Precision Medicines stock price valuation

P/E

N/A

P/B

2.43

P/S

632.44

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

515.72

PRAX's EPS has surged by 80% year-on-year and by 38% since the previous quarter

PRAX's equity has soared by 82% from the previous quarter

PRAX's P/B is 9% below its last 4 quarters average of 2.6

The price to sales (P/S) is 144% more than the last 4 quarters average of 251.6

The revenue has increased by 21% year-on-year but it has declined by 19% since the previous quarter

How efficient is Praxis Precision Medicines business performance

The company's return on invested capital has surged by 88% YoY and by 84% QoQ

Praxis Precision Medicines's ROE has soared by 66% YoY and by 40% from the previous quarter

Praxis Precision Medicines's ROA has soared by 57% YoY and by 36% from the previous quarter

PRAX's return on sales is up by 35% year-on-year but it is down by 22% since the previous quarter

What is PRAX's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for PRAX.

How did Praxis Precision Medicines financials performed over time

The total assets has soared by 76% QoQ

The quick ratio has soared by 55% since the previous quarter

The debt is 100% smaller than the equity

The debt to equity has dropped by 100% since the previous quarter and by 100% year-on-year

PRAX's equity has soared by 82% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.